THE MANAGEMENT OF PATIENTS WITH GAUCHER DISEASE, TYPE 1
Abstract
Background. Accumulation of glucocerebroside in spleen, liver, bone marrow and bones, but rarely in other organs, due to inborn deficiency of lisosomal enzyme glucocerebrosidase leads to Gaucher disease. The most common is type 1, chronic non-neuronopathic form of Gaucher disease. In type 1 the central nervous system is not affected and clinical presentations are variable. It could be a mild disease not necessitating therapy or a more severe one which sometimes results even in disability. In such cases the replacement enzyme therapy is reasonable and the dose should be adjusted to the severity of the illness. It improves the patient’s condition and prevents the progression of the disease.
Conclusions. This article emphasises the guidelines for the management of patients with Gaucher disease, type 1. Recommendations for diagnostic approach and follow up of the patients as well as groups of patients necessitating a replacement enzyme therapy at appropriate doses are defined and stated.
Downloads
References
Masek BJ, Sims KB, Bove CM et al. Quality of life in adults with type 1 Gaucher disease. Qual Life Res 1999; 8: 263–8.
Cox TM, Schofield JP. Gaucher’s disease: clinical features and natural history. Bailliere’s Clinical Haematology 1997; 10: 657–89.
Grabowski GA. Genetic aspects of Gaucher disease. Gaucher Clin Perspect 1993; 1: 5–9.
Grabowski GA. Gaucher’s disease: molecular, genetic and enzymological aspects. Bailliere’s Clinical Haematology 1997; 10: 635–56.
Erikson A. Neuronopathic forms of Gaucher’s disease. Bailliere’s Clinical Haematology 1997; 10: 711–23.
Aerts JMFG, Hollak CEM. Plasma and metabolic abnormalities in Gaucher’s disease. Bailliere’s Clinical Haematology 1997; 10: 691–709.
Brady RO. Gaucher’s disease: past, present and future. Bailliere’s Clinical Haematology 1997; 10: 621–34.
Zimram A. Lancet 1989; 2: 349–52.
Elstein D, Itzchaki M, Mankin HJ. Skeletal invollvement in Gaucher’s disease. Bailliere’s Clinical Haematology 1997; 10: 793–816.
Cremin BJ, Davey H, Goldblatt J. Skeletal complications of type 1 Gaucher disease: The magnetic resonance features. Clin Rad 1990; 41: 244–7.
Pastores GM, Wallenstein S, Desnick RJ et al. Bone density in type 1 Gaucher disease. J Bone Miner Res 1996; 11: 1801–7.
Hermann G. AJR 1986; 147: 943 – 8.
Damiano AM, Pastores GM, Ware JE. The health-related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 1998; 7: 373–86.
Niederau C, Ehlen C, Birkhahn A, Häussinger D. Facts and fiction in the modern diagnosis of Gaucher disease. Gaucher Clin Perspect 1996; 4: 5–13.
Pastores GM, Hermann G, Norton KI et al. Regression of skeletal changes in type 1 Gaucher disease with enzyme replacement therapy. Skeletal Radiol 1996; 25: 485–8.
Niederau C, Holderer A, Heintges T, Strohmeyer G. Glucocerebrosidase for treatment of Gaucher’s disease: first German long-term results. J Hepatol 1994; 21: 610–7.
Niederau C, Poll L, van Dahl S, Häussinger D. The spleen in Gaucher disease. Gaucher Clin Perspect 2001; 9: 14–23.
Fleshner PR, Aufses AH, Grabowski GA. A 27–year experience with splenectomy for Gaucher disease. Am J Surg 1991; 161: 69–75.
Grabowski GA, Barton NW, Pastores G et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122: 33–9.
Schaison G, Caubel I, Bematoug N et al. French results of enzyme replacement therapy in Gaucher’s disease. Bull Acad Natl Med 2002; 186: 851–61.
Ida H, Rennert OM, Kato S et al. Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inher Metab Dis 1999; 22: 63–73.
Charrow J, Esplin JA, Gribble TJ, Kaplan P, Kolodny EH, Pastores GM, Scott CR, Wappner RS, Weinreb NJ, Wisch JS. Arch Intern Med 1998; 158: 1754–60.
Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994; 93: 1288 – 92.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
